lodibet vip login philippines
lodibet vip login philippines
In conclusion, the blue and pink skin in "Assassin's Creed: Valhalla - Wrath of the Druids" has proven to be a contentious yet compelling addition to the game's customization options. Whether viewed as a bold and refreshing change or a jarring departure from the game's established aesthetic, one thing is certain - it has sparked passionate discussions and ignited the imaginations of players, demonstrating the enduring appeal of visual customization in gaming.Only time will tell what the outcome of the investigation into Prime Minister Yin Sui-yue and others will be, and how it will impact South Korea's political landscape in the days and weeks to come. One thing is certain: the nation stands at a critical juncture, where the decisions made in the wake of this internal turmoil will shape its future for years to come. - **Usage:** "I'm experiencing serious end-of-semester burnout. I just need to push through these last few days."
Late kickoff return TDs by Turpin and Thomas spark the Cowboys as they end their 5-game skid
Australian retailers selling themselves short by opting out of mega Black Friday shopping event, experts say
The poster captures the essence of the upcoming battle between the two teams, with a dynamic and captivating design that showcases the formidable lineup of Liverpool stars. Virgil van Dijk, the towering defender known for his commanding presence in the backline, is depicted in a powerful stance, ready to lead his team to victory with his defensive prowess and leadership on the pitch.
Robo-advisor CEOs team up to transform retirement pension marketThe exonerated Central Park 5 have mounted a forceful challenge to Donald Trump 's attempt to dismiss their defamation lawsuit , arguing his past presidential debate statements were demonstrably false and defamatory. In their November 22 response to Trump's motion, the men's attorneys systematically dismantled Trump's defense of his September 10 ABC News presidential debate remarks, declaring his claim that they "killed a person" was "fabricated from whole cloth." The filing in Pennsylvania federal court specifically challenges Trump on three points: his false assertion that they pled guilty to the 1989 Central Park assault , his inaccurate claim that someone was killed during the incident, and his omission of their complete exoneration more than twenty years ago. The controversy dates back to 1989 when Trump purchased a full-page New York Times advertisement calling for the death penalty's return to punish the then-accused group of teenagers. The men were later exonerated in 2002 after new DNA evidence emerged and another person confessed to the crime. New York City settled with them in 2014 worth approximately $40 million. Their attorneys emphasized that the men—who were between 14 and 16 years old and unrepresented by counsel at the time—gave false confessions which they "immediately recanted upon their release from police custody." According to the filing, citing the National Registry of Exonerations, roughly half of individuals exonerated following murder convictions involving DNA evidence since 1989 made false confessions. Newsweek contacted the Trump transition team via email on Saturday for comment. Trump's attorney, Karin Sweigart, had characterized the lawsuit as "legally insufficient and meritless," arguing his debate comments were "non-actionable opinion" and "substantially true" based on statements made during their 1989 arrests. The five men—Yusef Salaam, Antron McCray, Kevin Richardson, Raymond Santana, and Korey Wise—forcefully countered this interpretation. The response, filed by attorneys Shanin Specter and Alex Van Dyke, draws a stark distinction between coerced confessions and guilty pleas. Under Pennsylvania law, they argue, statements can be distinguished from opinions by whether they can be "objectively determined." Their filing notes Trump's statements can be "verified as true or false—they are both false." The men's lawyers also rejected Trump's invocation of Pennsylvania's anti-SLAPP statute, pointing out that district courts within the Third Circuit have concluded such statutes don't apply in federal court. They further rebuked Trump's characterization of the case as an attempt to "silence political discourse." The case stems from Trump's statements during the presidential debate when he said, "They admitted, they said they pled guilty and I said, 'well, if they pled guilty, they badly hurt a person, killed a person ultimately ... And they pled guilty, then they pled not guilty.'" Beyond defamation, the filing includes claims for casting them in a "false light" and intentional infliction of emotional distress. The attorneys cite Trump's alleged admission of wanting to make them "suffer... to punish them... to [make them] be afraid," describing this as a "public vendetta against five innocent men" that is "intolerable in a civilized society." The filing emphasizes that "accuracy is important when accusing individuals of serious crimes." They argue there is "a vast difference between a recanted confession and a guilty plea," noting that guilty pleas involve procedural safeguards and counsel representation absent during police interrogations. Judge Wendy Beetlestone, recently assigned after Trump's attorneys sought the previous judge's recusal over his personal relationship with Specter , will consider the arguments at a pre-Motion to Dismiss Conference scheduled for December 5, 2024.
FLORENCE, Italy & BARCELONA, Spain--(BUSINESS WIRE)--Dec 11, 2024-- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with MEDSIR, a leading global independent clinical research company in oncology and part of Oncoclínicas & Co., the largest specialized oncology treatment group in Latin America, presented research on the pioneering clinical trial ADELA. This important research addresses therapeutic resistance in advanced ER+/HER2- breast cancer. Presented at the San Antonio Breast Cancer Symposium 2024 (SABCS), the study represents a key milestone in the quest for more effective and personalized treatment options for patients with disease progression. The standard first-line treatment for advanced ER+/HER2- breast cancer combines endocrine therapy with CDK4/6 inhibitors. ESR1 mutations develop as a result of prior exposure to endocrine therapy during metastatic treatment, and up to 50% of ER+, HER2- advanced or metastatic breast cancers will develop these mutations. ESR1 mutations cause the tumors to become resistant to endocrine therapy, in turn causing the cancer to progress; therefore, it is important to test for ESR1 whenever mBC progresses. Longer exposure to endocrine therapy during first-line treatment increases the chance of a patient’s tumor developing an ESR1 mutation. With the goal of addressing this unmet medical need, the ADELA phase III clinical trial investigates a new therapeutic option combining elacestrant, a next generation, oral selective estrogen receptor degrader, with everolimus, an mTORC1 inhibitor. This combination is being evaluated in patients with advanced ER+/HER2- breast cancer that harbors ESR1 mutations, and who have experienced progression after standard first-line treatment. Results from the phase III EMERALD study were the basis for elacestrant’s approval. Meanwhile, everolimus has shown efficacy in inhibiting other resistance mechanisms in this type of cancer. The elacestrant and everolimus combination has demonstrated preliminary efficacy with a manageable safety profile in the phase 1b/2 ELEVATE study ( NCT05563220 ). “We at Menarini Stemline are delighted to announce the collaboration with MEDSIR to continue advancing the clinical research to explore the combination therapy with elacestrant,” said Nassir Habboubi, MD, Chief Medical Officer of Stemline Therapeutics. “We are committed to driving innovation in cancer treatment by delivering transformational therapies aiming to extend the lives of people living with cancer.” The primary objective of this international, randomized, double-blind trial is to evaluate whether the combination of elacestrant and everolimus offers greater efficacy in delaying disease progression compared to elacestrant monotherapy. Additionally, it investigates other crucial aspects, such as overall survival, toxicity profile, and the impact on patients’ quality of life. The ADELA study represents a critical step in understanding how to overcome tumor resistance challenges in patients with ESR1 mutations, with the goal of advancing towards more effective and safer treatments. “At MEDSIR, we understand innovation not only as achieving clinical results but as the ability to transform patients' lives on a global scale. With ADELA, we take a decisive step toward accomplishing less invasive and more accessible treatments, aiming to offer new hope to those facing the most complex forms of the disease. This advancement reinforces our commitment to increasingly personalized and patient-centered medicine, a fundamental pillar in shaping the future of oncology,” said Dr. Antonio Llombart-Cussac, Senior Scientific Leader at MEDSIR. The phase III study not only has significant clinical objectives, but also holds the potential to pave the way for regulatory approval of this therapeutic combination, enabling its use in a broader population of patients with advanced breast cancer. Moreover, the international scope of the study, which includes participation from multiple countries, including Spain, Italy, France, Austria, the Czech Republic, Greece, Germany, and the United Kingdom, underscores the study’s global importance and relevance in the scientific community. The presentation of the ADELA study at an event as prominent as SABCS 2024 reinforces MEDSIR’s leadership in excellence-driven oncology research and highlights its focus on addressing unmet needs in breast cancer treatment. The ADELA study is active and already recruiting patients. About ORSERDU (elacestrant) U.S. Indication: ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Full prescribing information for the U.S. can be found at www.orserdu.com . Important Safety Information Warning and Precautions Dyslipidemia : Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively. Monitor lipid profile prior to starting and periodically while taking ORSERDU. Embryo-Fetal Toxicity : Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the final dose. Adverse Reactions Serious adverse reactions occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each). The most common adverse reactions (≥10%) , including laboratory abnormalities, of ORSERDU were musculoskeletal pain (41%), nausea (35%), increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite(15%), diarrhea(13%), headache (12%), constipation (12%), abdominal pain (11%), hot flush (11%), and dyspepsia (10%). Drug interactions Concomitant use with CYP3A4 Inducers and/or inhibitors : Avoid concomitant use of strong or moderate CYP3A4 inhibitors with ORSERDU. Avoid concomitant use of strong or moderate CYP3A4 inducers with ORSERDU. Use in specific populations Lactation : Advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose. Hepatic Impairment : Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B). The safety and effectiveness of ORSERDU in pediatric patients have not been established. To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . About The Menarini Group The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $4.7 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. For further information, please visit www.menarini.com . About Stemline Therapeutics Inc. Stemline Therapeutics, Inc. (“Stemline”) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes ORSERDU ® (elacestrant) in the U.S. and Europe, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline also commercializes ELZONRIS ® (tagraxofusp-erzs), a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States and Europe, which is the only approved treatment for BPDCN in the U.S. and E.U. to date. Stemline also commercializes NEXPOVIO ® (selinexor) in Europe, an XPO1 inhibitor for multiple myeloma. Stemline also has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers. About MEDSIR Established in 2012, MEDSIR prides itself on working closely with its strategic partners to drive innovation in oncology research. Operating in Spain and the United States, the company provides end-to-end clinical trial management, from study design to publication, with an extensive global network of experts and integrated technology to streamline the process. The company offers proof-of-concept support and a strategic approach that enables research partners to benefit from the best of both worlds: industry clinical research and investigator-driven trials. With the aim of promoting independent research worldwide, MEDSIR has formed a strategic alliance with Oncoclínicas, the leading oncology group in Brazil, which offers outstanding research potential in South America. For further information: www.medsir.org About Oncoclínicas & CO Oncoclínicas&Co is the largest group dedicated to cancer treatment in Latin America, with a specialized and innovative model focused on the entire oncology care journey, combining operational efficiency, humanized care, and high specialization through a medical team composed of over 2,700 specialist physicians with an emphasis on oncology. With its mission to democratize cancer treatment, it offers a comprehensive system that integrates outpatient clinics with high-complexity cancer centers. The company operates 145 units across 39 Brazilian cities, allowing high-quality access in all regions it serves, aligned with world-class standards. Focusing on technology, precision medicine, and genomics, Oncoclínicas performed approximately 635,000 treatments in 2023. It is the exclusive partner in Brazil of the Dana Farber Cancer Institute, affiliated with Harvard Medical School, one of the world’s leading cancer research and treatments centers. The company also owns Boston Lighthouse Innovation, a bioinformatics firm based in Cambridge, United States, and holds shares in Medsir, a company dedicated to the development and management of clinical trials for independent cancer research, based in Barcelona, Spain. Recently, Oncoclínicas expanded its operations to Saudi Arabia through a joint venture with the Al Faisaliah Group, bringing its mission to beat cancer to a new continent and providing advanced oncology care on a global scale by combining oncological hyperspecialization with innovative treatment approaches. The company is part of the IDIVERSA index, launched by B3, highlighting companies committed to gender and racial diversity. For more information, visit: www.grupooncoclinicas.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20241211008868/en/ CONTACT: Media Contacts The Menarini Group Valeria Speroni Cardi Email:pressoffice@menarini.comStemline Therapeutics, Inc. Cheya Pope Email:media@menarinistemline.comGlobal Brand Communication MEDSIR: Sergio Aguilar Global Brand & Communication Director +34 674 82 87 24 sergio.aguilar@medsir.orgEduardo Martín Espallargas Global Communication & Marketing Manager +34 634 835 389 Eduardo.martin@medsir.orgCarles Berloso Cortés International PR & Comms +34 677 49 75 23 carles.berloso@medsir.org KEYWORD: TEXAS SPAIN NORTH AMERICA UNITED STATES EUROPE ITALY INDUSTRY KEYWORD: RESEARCH CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE ONCOLOGY SOURCE: The Menarini Group Copyright Business Wire 2024. PUB: 12/11/2024 06:35 PM/DISC: 12/11/2024 06:35 PM http://www.businesswire.com/news/home/20241211008868/en
NoneMalik Nabers says calling the Giants 'soft' was wrong but he doesn't regret speaking outIn this episode of , Jason Fitz and Frank Schwab dive into the fallout from every game of Week 17 NFL action, from a looming monster matchup to a coaching decision that could change the landscape of the 2024 season. Fitz and Frank agree: next week’s showdown between the Minnesota Vikings and Detroit Lions is one of the most high-stakes regular season games of all time, and Campbell has a huge decision to make about whether or not to sit players on Monday night. As the duo breaks down the week’s key matchups, they touch on Sam Darnold’s explosive performance for the Vikings, why the Green Bay Packers still haven't proven they can beat top teams and how the Los Angeles Chargers are shaping up for a playoff run. The Denver Broncos suffered a heartbreaking loss to the Cincinnati Bengals with playoff hopes on the line, while the New York Jets’ disastrous performance against the Buffalo Bills raised even more questions about their future. Fitz and Schwab also dig into Brock Bowers breaking records and the Indianapolis Colts’ playoff chances crumbling with a disastrous performance. Fitz and Schwab also weigh in on the fate of Mike McCarthy after the Dallas Cowboys’ embarrassing loss to the Philadelphia Eagles and the rest of the Sunday slate before giving their uncertain predictions for an awkward Monday night matchup between the Detroit Lions & San Francisco 49ers. (1:50) - Week 18 battle for home field advantage (11:00) - Green Bay Packers @ Minnesota Vikings (22:00) - Atlanta Falcons @ Washington Commanders (31:00) - Los Angeles Chargers @ New England Patriots (35:00) - Denver Broncos @ Cincinnati Bengals (39:00) - Arizona Cardinals @ Los Angeles Rams (40:50) - New York Jets @ Buffalo Bills (44:30) - Dallas Cowboys @ Philadelphia Eagles (47:50) - Las Vegas Raiders @ New Orleans Saints (52:00) - Indianapolis Colts @ New York Giants (57:20) - Tennessee Titans @ Jacksonville Jaguars (58:20) - Miami Dolphins @ Cleveland Browns (59:40) - Carolina Panthers @ Tampa Bay Buccaneers (1:02:50) - MNF preview
In conclusion, Haier's firm denial of the layoff rumors and its pledge to pursue legal responsibility against those spreading misinformation send a clear signal that the company takes its reputation and the well-being of its employees seriously. By standing up against false rumors and holding accountable those who seek to sow discord and confusion, Haier reaffirms its commitment to honesty, integrity, and trustworthiness in all its endeavors.Behind Donald Trump's Win, The Misplaced Optimism Of The White Liberal
The news of Liu's death spread quickly across social media, with many expressing disbelief and sorrow at the untimely passing of the popular internet personality. As details of the events leading up to her death emerged, questions were raised about the safety of cosmetic procedures and the risks associated with them.
What sets Lee Gang-in apart from other players in terms of merchandise sales is his online presence. While Mbappé may have a larger following and more widespread recognition, it is Lee who is leading the pack in online jersey sales. This phenomenon can be attributed to a combination of factors, including Lee's unique playing style, his social media presence, and his strong connection with fans both in South Korea and around the world.
190 athletes are competing at the Taekwondo Winter Classic Tournament with hopes of being crowned a champion – but winning isn’t all this competition is about – as it focuses on developing young athletes and allowing them to envision a future in this sport. “This is very important for taekwondo in Manitoba because it is opening up and giving an outside look into our taekwondo world,” said Master Kristy Tam, Owner & Coach at Tam’s Taekwondo. “We’ve seen actually quite a bit of growth since the Olympics, with Skylar Park winning a bronze medal everyone want to get a piece of the action and learn more about it,” said Kim BedonaPadua, President of Taekwondo Manitoba. Competing with mainstream sports like hockey, football, and basketball, taekwondo has faced challenges over the years. However, by producing athletes who have reached levels as high as the Olympics, interest in the sport has spiked in Manitoba over the past few years. “The sport has grown so much where there’s little kids from 5 years old to adults 70, 80, taekwondo is for everyone and no matter what direction you’re wanting to go in we have many different paths so it’s great,” said Tam. “As an adult I have my kids ask hey mom can I do taekwondo? And it’s like YES! And I figured you know what, it’s time for me to get back in and it’s a family thing and a really really great bonding experience for us,” said Aryanne Lu Cruz, Taekwondo Athlete. The Winter Classic featured athlete weigh-ins on Friday, followed by a showcase of poomsae patterns and intense sparring matches on Saturday to close out the tournament. “There’s two sides of taekwondo there’s the art of taekwondo where they do the poomsae which is patterns and very traditional, and then there’s the Olympic sport where Skylar Park and all of the fighters go to,” said BedonaPadua.NFL Week 18 schedule: Matchups, times, Vikings-Lions headlines regular-season finale
First and foremost, the robust performance of the A-share market can be largely attributed to the strengthening of the Chinese currency, the Renminbi (RMB). As the RMB continues to rise against major global currencies, such as the US dollar and the Euro, investors are increasingly attracted to Chinese stocks as a lucrative investment option. The appreciation of the RMB not only enhances the purchasing power of domestic investors but also bolsters the confidence of foreign investors, further propelling the A-share market to new heights. This increase in currency value has created a bullish sentiment across the market, driving up stock prices and triggering a wave of limit-up stocks.Beacon Healthcare Systems Expands Leadership Team with Addition of Ayman Mohamed as Chief Technology Officer
Friendly reminder |
The authenticity of this information has not been verified by this website and is for your reference only. Please do not reprint without permission. If authorized by this website, it should be used within the scope of authorization and marked with "Source: this website". |
Special attention |
Some articles on this website are reprinted from other media. The purpose of reprinting is to convey more industry information, which does not mean that this website agrees with their views and is responsible for their authenticity. Those who make comments on this website forum are responsible for their own content. This website has the right to reprint or quote on the website. The comments on the forum do not represent the views of this website. If you need to use the information provided by this website, please contact the original author. The copyright belongs to the original author. If you need to contact this website regarding copyright, please do so within 15 days. |